Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

NCT06669403 is registered in ClinicalTrials.gov with Op-T LLC as lead sponsor.

NCT NCT06669403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06669403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
Lead sponsor
Op-T LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
May 31, 2026
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

community acquired pneumonia (cap), sepsis